Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.

ABSTRACT:

Objective

Participants in ADVANCE were drawn from many countries. We examined whether the effects of intensive glycemic control on major outcomes in ADVANCE differ between participants from Asia, established market economies (EMEs), and eastern Europe.

Research design and methods

ADVANCE was a clinical trial of 11,140 patients with type 2 diabetes, lasting a median of 5 years. Demographic and clinical characteristics were compared across regions using generalized linear and mixed models. Effects on outcomes of the gliclazide modified release-based intensive glucose control regimen, targeting an HbA(lc) of ≤6.5%, were compared across regions using Cox proportional hazards models.

Results

When differences in baseline variables were allowed for, the risks of primary outc

SUBMITTER: Woodward M 

PROVIDER: S-EPMC3220831 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature